Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. (Q51998598)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Donatella Negri

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Roberta Bona

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Jonathan L. Heeney

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Maria Teresa Maggiorella

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

S Baroncelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Zuleika Michelini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Antonella Caputo

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Barbara Ridolfi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Massimo Ciccozzi

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Barbara Ensoli

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Emanuele Fanales-Belasio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Sonia Moretti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Leonardo Sernicola

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Stefano Buttò

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Valeria Fiorelli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Antonella Tripiciano

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Arianna Scoglio

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Alessandra Borsetti

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Peter ten Haaft

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Iole Macchia

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Pasqualina Leone

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Maria Rosaria Pavone-Cossut

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Filomena Nappi

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Fausto Titti

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Aurelio Cafaro

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

English

0 references

publication date

1 September 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

25-26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

3258-3269

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15308348%20AND%20SRC:MED&resulttype=core&format=json

Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

The trans-activator gene of HTLV-III is essential for virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Regulatory pathways governing HIV-1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Regulation of Cellular Gene Expression and Function by the Human Immunodeficiency Virus Type 1 Tat Protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Cellular uptake of the tat protein from human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Tat-mediated delivery of heterologous proteins into cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Tat protein is an HIV-1-encoded beta-chemokine homolog that promotes migration and up-regulates CCR3 expression on human Fc epsilon RI+ cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Vaccination with Rev and Tat against AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

NOVEL STRATEGIES TOWARD THE DEVELOPMENT OF AN EFFECTIVE VACCINE TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION OR ACQUIRED IMMUNODEFICIENCY VIRUS*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Determining the immune mechanisms of protection from AIDS: correlates of immunity and the development of syngeneic macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Rational development of prophylactic HIV vaccines based on structural and regulatory proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Longitudinal human immunodeficiency virus type 1 load in the italian seroconversion study: correlates and temporal trends of virus load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

New insight on the role of extrachromosomal retroviral DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Unintegrated circular HIV-1 DNA in the peripheral mononuclear cells of HIV-1-infected subjects: association with high levels of plasma HIV-1 RNA, rapid decline in CD4 count, and clinical progression to AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Viral DNA burden and decline in percentage of CD4-positive cells in the lymphoid compartment of SIV-infected macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Design and In Vivo Immunogenicity of a Polyvalent Vaccine Based on SIVmac Regulatory Genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

7 January 2021

Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

7 January 2021

A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

7 January 2021

The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

7 January 2021

Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

7 January 2021

Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.009

7 January 2021